Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary
- PMID: 36638048
- DOI: 10.1111/bju.15966
Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary
Keywords: cava thrombus; neoadjuvant; systemic treatment; thrombus; tyrosine kinase inhibitor.
References
-
- Kirkali Z, Van Poppel H. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol 2007; 52: 658-62
-
- Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 2004; 94: 33-41
-
- Field CA, Cotta BH, Jimenez J et al. Neoadjuvant sunitinib decreases inferior vena Caval thrombus size and is associated with improved oncologic outcomes: A multicenter comparative analysis. Clin Genitourin Cancer 2019; 17: e505-12
-
- GRADE handbook [Internet]. Available at: https://gdt.gradepro.org/app/handbook/handbook.html. Accessed 2022 December 21
-
- Tanaka Y, Hatakeyama S, Hosogoe S et al. Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava. Int J Clin Oncol 2018; 23: 134-41
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical